Compounds, compositions, and methods of use thereof
By developing drugs containing compounds of formula (I) or (II), the problem of CFTR protein dysfunction in cystic fibrosis has been solved, and effective treatment and symptom improvement of the disease has been achieved.
CN119677730APending Publication Date: 2025-03-21SIONNA THERAPEUTICS INC
31 Cites 0 Cited by
Patent Information
- Application Number
- CN202380058226.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-10
- Filing Date
- 2023-06-09
- Publication Date
- 2025-03-21
AI Technical Summary
Technical Problem
The deletion or dysfunction of CFTR protein in patients with cystic fibrosis leads to exocrine dysfunction and multisystem diseases, and existing treatments cannot effectively cure this disease.
Method used
A drug comprising a compound of formula (I) or (II) is developed to treat cystic fibrosis and other CFTR-mediated diseases by its pharmaceutically acceptable salts and methods of use.
Benefits of technology
This compound can effectively regulate the function of CFTR channels, improve clinical symptoms in patients, reduce the severity of the disease, and provide new methods for treating CFTR-related diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical formulations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and disorders mediated by deficient CFTR activity, in particular cystic fibrosis.
Need to check novelty before this filing date? Find Prior Art